登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>CD19 >CHEK-ATP003

HEK293/Human CD19 Stable Cell Line

For research use only.

描述(Description)

HEK293/Human CD19 Stable Cell Line

应用说明(Application)

For cell-based binding assays

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puro (10 μg/mL)

培养基(Culture Medium)

DMEM + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

活性(Bioactivity)

CD19 FACS

Fig. FACS analysis of CD19 on HEK293/Human CD19 Stable Cell Line.
FACS assay shows that Biotinylated FMC63 scFv, Fc,Avitag can bind to HEK293/Human CD19 Stable Cell Line. HEK293/Human CD19 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD19靶点信息
英文全称:B-lymphocyte antigen CD19
中文全称:B淋巴细胞抗原CD19
种类:Homo sapiens
上市药物数量:11详情
临床药物数量:291详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细
相关产品
View All CD19

消息提示

请输入您的联系方式,再点击提交!

确定